Article Information
- Received June 26, 2013
- Revision received April 2, 2014
- Accepted April 10, 2014
- First published May 21, 2014.
- Version of record published May 21, 2014.
Author Information
- Matthew R. Durk1,
- Kyung Han3,
- Edwin C. Y. Chow1,
- Rosemary Ahrens3,
- Jeffrey T. Henderson1,
- Paul E. Fraser2,3, and
- K. Sandy Pang1
- 1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada, M5S 3M2,
- 2Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada, M5S 3H2, and
- 3Tanz Centre for Research in Neurodegenerative Diseases, Krembil Discovery Tower, Toronto, Ontario, Canada, M5T 2S8
Author contributions
Author contributions: M.R.D., R.A., J.T.H., P.E.F., and K.S.P. designed research; M.R.D., K.H., R.A., and J.T.H. performed research; E.C.Y.C., R.A., J.T.H., P.E.F., and K.S.P. contributed unpublished reagents/analytic tools; M.R.D., K.H., R.A., and J.T.H. analyzed data; M.R.D., K.H., and K.S.P. wrote the paper.
Disclosures
- Received June 26, 2013.
- Revision received April 2, 2014.
- Accepted April 10, 2014.
This work was supported by the Canadian Institutes of Health Research (CIHR) and the Alzheimer Society of Ontario. M.R.D. was supported by a CIHR Strategic Training Grant in Biological Therapeutics and Pfizer Canada Graduate Scholarship in Science and Technology. E.C.Y.C. was supported by the Natural Sciences and Engineering Research Council of Canada Alexander Graham Bell Fellowship. We thank Dr. Bingning Dong (Baylor College of Medicine, Texas Medical Center, Houston, TX) for discussion on immunostaining.
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. K. S. Pang, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, Canada, M5S 3M2. ks.pang{at}utoronto.ca
